Immune Therapeutics, Inc. | Business Finance | Business Contracts

Convertible Promissory Note in the Principal Amount of $100,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps (Filed With SEC on July 22, 2022)

Convertible Promissory Note in the Principal Amount of $200,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps (Filed With SEC on July 22, 2022)

Term Sheet (Filed With SEC on July 7, 2022)

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey (Filed With SEC on March 18, 2022)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey (Filed With SEC on March 18, 2022)

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey (Filed With SEC on May 24, 2021)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey (Filed With SEC on May 24, 2021)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on April 15, 2021)

Amendment to the Articles of Incorporation filed February 5, 2020 approving a reverse split of issued and outstanding shares of common stock by 1,000 to 1 (Filed With SEC on August 14, 2020)

Amendment to the Articles of Incorporation filed March 12, 2020 approving an increase in authorized shares of common stock from 500,000,000 to 750,000,000 (Filed With SEC on August 14, 2020)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on May 14, 2020)

Convertible Promissory Note dated March 30, 2020 to Redstart Holdings Corp. in the principal amount of $53,000 (Filed With SEC on May 14, 2020)

Mutual Release and Non-Disparagement Agreement effective April 30, 2020 (Filed With SEC on May 5, 2020)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on May 20, 2019)

Letter to Shareholders (Filed With SEC on May 15, 2019)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on April 16, 2019)

Immune Therapeutics, Inc. (105) | Business Finance (23)